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Chapter 1 
HIV technologies 
Mark Davis and Corinne Squire 
 
HIV technologies, treatment possibility and health governance 
This edited collection addresses the governance of the HIV and AIDS pandemic with 
reference to the social aspects of technology in international contexts. The term 
'technology' is used to encompass medical technologies such as HIV treatment, but 
also other ‘technologies’ of health care, including psychosocial and social 
interventions and communications media applied to moderating HIV's impact and to 
preventing HIV transmission. HIV technologies of the biomedical kind have become a 
focus in the research and policy literature. Policy frameworks advocate for close 
attention to the relationship between HIV treatment and prevention (Global HIV 
Prevention Working Group, 2008: 6)(see also Mykhalovskiy, this volume) and an 
address to ‘psychosocial’ factors (UNAIDS, 2009b), as well as integration between 
HIV and other health and social policy initiatives, around for instance TB, drug use, 
and gender-based violence (UNAIDS, 2009a). Researchers have warned of the need to 
consider the social and cultural dimensions of biomedical interventions (Peltzer et al., 
2007) such as male circumcision. This volume contributes to these debates by 
investigating the social and cultural dimensions of HIV technologies that find 
expression in different parts of the world.  
 
While there has been much written about the HIV pandemic, recent social scientific 
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research is largely directed at description and policy improvement. For some time now 
we have lacked a sustained social science engagement with the pandemic that 
addresses the changing technologies of its governance. We also lack texts that 
consider HIV technologies globally.  From time to time, inspiring research does 
appear in the literature, some of it produced by the contributors to this collection. 
However, we argue that there is still a need to bring together, and reflect on, 
theoretically informed, innovative research from different parts of the world 
concerning the current circumstances of the HIV/AIDS pandemic. 
 
HIV/AIDS is now a true pandemic, affecting people in all parts of the world. 
UNAIDS (2008) suggests 33 million people are living with HIV worldwide, with 
generally decreasing numbers of new infections, but increasing prevalence in for 
example the UK, Germany, Ukraine, the Russian Federation, China, Indonesia, Papua 
New Guinea, Mozambique and Vietnam, and stable but extremely high prevalence in 
a number of southern African countries. Prevalence is also high within particular 
groups in some regions - for instance, among black people in the US (Centers for 
Disease Control, 2009) - and new infections among gay men are increasing in western 
Europe and North America (UNAIDS, 2008). The pandemic is also radically dynamic 
and uncertain. For example, HIV prevalence in Uganda fell in the 1990s and then 
stabilised; now, sexual behaviours that carry HIV transmission risk are reported to be 
rising (UNAIDS, 2008). Many prevalence estimates are problematic and contested 
and error-prone, as indicated in India’s National AIDS Control Organisation’s 2007 
halving of its prevalence figures on the basis of expanded surveillance. 
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One of the key dimensions of the HIV pandemic was the development of HIV 
treatment in the mid-1990s. Up to that time, we lacked effective anti-viral treatment 
for HIV infection. In the mid 1990s however, combinations of anti-viral drug 
treatments, now most commonly referred to as Anti-Retroviral Therapy, or ART, were 
found to inhibit viral replication, therefore preventing the deterioration of, and in 
many cases restoring, the immune systems of people with HIV. Such advantageous 
medical technologies have had multiple effects. In the affluent countries of the 
developed world, they have changed the apocalyptic character of public discourse 
regarding HIV and AIDS. Today in the developed world, HIV is often characterised as 
a chronic and manageable disease. Improved treatment technologies have changed the 
shape of developed-world HIV advocacy and activism. Earlier community action 
projects were predicated on the imperatives of non-discrimination, care provision, 
education, transmission reduction and treatment advocacy. In the post-treatment 
situation, community action has come to focus on the politics of treatment rationing, 
and on short- and long-term difficulties and possibilities involved with ART such as 
treatment compliance, side-effects, drug ‘holidays’, simplified medication regimes 
and the development of new lines of ART. New kinds of relationships between people 
with HIV and medical services have also been fashioned, often governed by a 
pronounced medicalised rationality and focused on the technological control of the 
virus in the body of the individual patient. These technologised relations also include: 
negotiated relationships between doctors and 'expert' patients; increasingly long 
periods of medicated but unmonitored, ‘normalised’, HIV life; the common parallel 
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use of complementary and alternative medicine; experiences or expectations of ART 
problems and failure. Because ART reduces viral activity, debate has also focused on 
ART’s impact on the chance of HIV transmission in sexual intercourse, and how 
people with HIV address this knowledge in their sexual relationships. These aspects 
of HIV treatment and prevention raise new and urgent questions about how to 
effectively prevent HIV infections in this era of apparently treatment-led epidemic 
management. Has prevention become a secondary concern; how is medicalisation 
affecting prevention technologies; what new formations of community, citizenship 
and activism now inflect prevention? 
 
Such complexity intersects with local circumstances, underlining the tremendous 
challenge of reflecting on the global pandemic. A public discourse of HIV treatment 
possibility, twinned with treatment’s unavailability, dominates in most developing-
world contexts. Here though, despite expectations of improved treatment outcomes in 
well-resourced, mainly urban communities, access to full and first-line, rather than 
third world-‘appropriate’ treatment, is the primary demand of advocates and activists. 
As in the developed world, power in relation to treatment technologies is at issue – 
but the political rather than the medical shape of that power is foregrounded. 
UNAIDS's '3 by 5' programme, promising to provide ART for 3 million people by 
2005, reached its target at the end of 2006. Today, treatment reaches four million 
people (UNAIDS, 2009a), under half those currently thought to require ART. The G8 
and the African Union have pledged to provide 'universal' ART access by 2010; one 
of the Millenium Development Goals is to halt HIV’s spread by 2015. These goals 
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will be difficult to meet. Health and social care practitioners in the developing world 
face large challenges when implementing HIV treatment in highly resource-
constrained circumstances and in an overall framework of postcolonial global 
exploitation. There is strong competition for HIV resources from other health, social 
and economic constituencies. Client requirements for food, education, employment 
and gender equity and non-violence, often go far beyond HIV service providers’ remit. 
International aid organisations’ financial and practical provision varies not just with 
recipient organisations’ performance, but with national political positions. 
International pharmaceutical corporations resist expanding provision; developed-
world donor fatigue sets in. In the face of a raft of other economic, social and political 
difficulties, AIDS fatigue characterises many high-prevalence nations themselves. 
Developing-world HIV prevention programmes are also problematically situated, 
sometimes presented by international agencies as a kind of developing-world 
‘alternative’ to treatment, often addressed outside the requisite broader cultural and 
development frameworks that nations with high HIV prevalence themselves 
emphasise. Currently, such programmes are tending towards medicalised yet patient-
centred, low-technological initiatives such as microbicides and circumcision. 
 
The advent of effective HIV treatment has sharpened focus on disparities in treatment 
access and delivery between different parts of the globe. However, similar disparities 
exist within countries, where refugees cannot secure fully-fledged citizenship and the 
related rights to health care, where racialised, sexualized, gendered and economically 
disempowered social groups experience HIV service exclusion, and where HIV 
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service provision may differ radically between geopolitical areas and across urban and 
rural communities. The various histories and epidemiologies of HIV epidemics, 
different levels of prevalence, varieties of political ownership and response, and 
widely divergent resource availability also strongly differentiate prevention and 
treatment technologies.  
 
Across all these situations, ART has nevertheless defined ‘new’, post-treatment or 
treatment possibility generations, emerging in the mid-1990s in the developed world 
and post-2003 in most developing countries. These generations differ widely in the 
medical and other resources available to them, but have some potentially shared 
assumptions about living with HIV and the ‘risks’ of HIV transmission. HIV positive 
people taking ART in the developing world are also now having similar experiences 
of living long-term with HIV medication to people in developed-world countries. 
However, in the developing world, this group continues to live alongside large 
numbers of people who need but who cannot access ART, as well as large numbers of 
people newly infected each year. Moreover, effective treatment, or its possibility, 
arrived at very particular times within each epidemic. For instance, ART became 
available only after many HIV-positive people in developed countries and some 
African countries such as Uganda and Tanzania had died. Within other low-resourced 
countries such as South Africa, where the epidemic developed later, this second, 
‘post-treatment’ or ‘treatment-possibility’ generation involves people doing well on 
ART, living alongside many who are dying. This book reflects on these and other 
developments in the ‘post-treatment’ or ‘treatment-possibility’ period.  
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We are adamant that this book is not a tale of two pandemics delineated by the 
technological haves and have-nots: the ART-rich and the ART-deprived worlds of 
AIDS, which map troublingly though inexactly onto low- and high-prevalence 
epidemics in high- and middle- or low-income countries; declining or stable-
prevalence HIV world of prevention success in some countries and increasing 
prevalence in others. Instead, we suggest that there are multiple, intercalated 
epidemics, even within single countries. The possibilities of more effective treatment 
since the mid 1990s; an international commitment to developing-world treatment 
delivery since 2003; new approaches to prevention that address empowerment, 
especially women’s empowerment; engagements with the prevention capabilities of 
treatment; and an increasing commitment to interrelating treatment with prevention 
have contributed to a distinct moment within the pandemic. This moment has different 
characteristics across developed and developing worlds and low and high prevalence 
contexts, but rests in all these cases on treatment possibility, alongside an increasing 
recognition of the long-term, shifting and widely diffused character and effects of the 
pandemic. 
 
Aside from changes in the technological governance of HIV and questions over how 
to engage properly with its global and local impacts, there have also been theoretical 
developments in the study of technologies and health that are significant for the HIV 
field. The intensified technologisation of health care raises questions concerning the 
‘lay’ public’s engagement with science and technology, and with increasingly 
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scientised and managerial forms of governance. One set of concerns lies with how 
such managerial technologism reformulates relationships between the producers and 
consumers of healthcare, and the implications of this reformulation for the politics of 
expertise, and personal and ‘human’ security. There is a rapidly unfolding debate 
concerning how to frame and investigate these developments in theoretical and 
methodological terms. For example, perspectives such as the analysis of socio-
technological assemblages (Rose, 2007), biosociality (Rabinow, 1999), health 
citizenship (Robins, 2009), political economy (Webster, 2007) and psychosocial 
analyses (Davis, 2009) among others, have been applied to technologies and health 
governance. In addition, current critical perspectives on health governance engage 
policy shifts that have come to enshrine the ‘prudent’, risk averse individual as the 
prerequisite of all human agency (Fox & Ward, 2006; Ward et al., 2006). Such 
perspectives also challenge formulations of the neo-liberal subject of governance that 
delineate ‘health’ through assumptions about individual rights and responsibilities. 
With different emphases, these approaches to health and technologies therefore take 
up concerns about governmentality as opposed to narrow notions of ‘governance’. 
That is.they address the discourses, practices and resources by which modern states 
generate governance by producing and controlling their subjects as citizens (Foucault, 
1991).  
 
We argue that social research on the technologised and transnational HIV pandemic 
has much to contribute to debates concerning health and technologies, in terms of 
empirical and theoretical insight and because of the local and global complexity that 
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characterises the pandemic. The book thus provides a way to interrogate intensified 
processes of technologisation and transnationalism through the lens of HIV, with 
strong implications for discourses and practices of health governance in their broader 
substantive and theoretical contexts. 
 
HIV technologies and social inquiry 
There are many ways of taking social inquiry to health technologies. In this part of the 
introduction we would like to note several perspectives that the reader will identify in 
the chapters to follow or that help frame the overall argument of the volume, in order 
to make connections with wider debates concerning health governance. In particular, 
we make mention of analyses of the political economy of health technologies, recently 
discussed by Andrew Webster in his book Health, Technology and Society (2007). We 
also refer to the ways in which health technologies, and not least those used to treat 
and prevent HIV, have implications for risk calculus and identity (Adkins, 2002; 
Lupton & Tulloch, 1998). Many of the chapters draw on Foucauldian notions of 
governance as governmentality, and in particular Nikolas Rose’s conceptualisation of 
biopolitics (2007) and to a lesser extent, Paul Rabinow’s related articulation of 
biosociality (1999). For that reason we also make note here of some of the key aspects 
of these formulations of health governance. We also draw on Chantal Mouffe’s  
(2006) conceptualisation of contested and multipolar politics, because of the ways in 
which this approach draws attention to the complexities of different biopolitical 
locations, so characteristic of the ART possibility era and its expressions in different 
parts of the world.  
17 
 
 
 
 
 
A key strategy for this volume that the reader will recognise throughout is its address 
to health technologies, and therefore HIV technologies, as socio-technical systems or 
assemblages, rather than as apparatuses merely surrounded and modified by social 
formations. This perspective on technologies as simultaneously cause and effect of 
society is that outlined by Webster in his 2007 book. Health technologies can emerge 
inside the health field through the action of practitioners and patients, but they can 
also be produced less directly by medical researchers and pharmaceutical 
corporations’ efforts to limit and control disease. Some technologies have origins 
entirely outside the health field but come to affect it, for example, information 
technologies from business and industry. Webster also draws attention to the ‘who’ of 
technological innovation. For him, the actors are multiple and all need to be taken into 
account to understand health technologies. Such actors include government, 
commerce, consumers, researchers and media. Analysis of these circumstances 
involves examining how the various actors of health technologies interact, what social 
effects they produce and the claims on knowledge and expertise that support such 
effects. Analysis can also take up struggles and conflicts over health technologies to 
spur their theoretical elaborations. As will become plain, many of the chapters in this 
volume draw on this approach to elaborate the social and governmental dimensions of 
HIV technologies.  
 
Contemporary health technologies, including HIV technologies, are also seen by some 
analysts as linked with the focus on risk and risk management in health care (Lupton, 
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1999). Many of the biomedical technologies typically associated with HIV impinge on 
risk perception and more particularly risk behaviour. For example, one’s sexual or 
drug using practices might put one at risk of HIV infection. HIV treatment is itself 
suffused with risk calculations. For example, the ongoing management of ART relies 
on clinical markers such as CD4 counts, viral load and viral genotyping that are used 
to judge the risk of treatment failure and inform modifications of treatment. Questions 
of superinfection with drug resistant forms of HIV are also couched in terms of risk 
for the person with HIV. Researchers and HIV educators have examined the extent to 
which the knowledge generated by ART and the blood tests used to support it 
influence risk behaviour (Elford, 2006). A central concept here is ‘disinhibition’, or 
‘treatment optimism’ as it is sometimes called, which is the idea that the health 
benefits of ART reduce motivation to avoid risky sexual behaviours (Van De Ven et 
al., 2004). As has been argued however, such uses of risk are methods of governance. 
For Lisa Adkins, risk is not so much a challenge for late modern subjects as a method 
by which such subjects come into being (2002). According to Kane Race, the risk 
knowledge systems that proliferate in and around HIV treatment have the effect of 
drawing attention to the practices of people who use these technologies, particularly in 
connection with sexual relations and ART dosing (2001, and also in this volume). As 
many chapters in this volume demonstrate, a critique of dimensions of risk 
management is central to the analysis of HIV technologies.  
 
The risk-related forms of subjectivity and requirements on sexual and drug-dosing 
practices noted by writers such as Adkins and Race indicate that biomedical HIV 
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technologies are more than just substances and tools. While impinging on the action 
of the virus in bodies, they are also vehicles for social effects in the lives of people 
affected by HIV. By extension, it is also possible to argue that social practices are 
‘technological’ in the sense of the effects they mobilise in and through materiality, 
bodies and social relations. This expanded notion of HIV technologies is important to 
this volume because it allows us to consider the various biomedical, but also social 
and governmental technologies that are used to address HIV. This perspective opens 
up the prospect that HIV technologies can be ostensibly biomedical as in ART, but 
also social, such as in HIV prevention or care interventions. It also demonstrates that 
the various dimensions of technology are present in all attempts to address HIV, that 
is, ART is always a social and political treatment and HIV prevention has material 
mediations, expressions and effects. After all, HIV treatment and prevention are 
joined in the sense that they both address a viral entity and seek to operate on it. 
Furthermore, HIV is itself dependent on social relations and cultural practices, 
engagement with which is constitutive of all manner of HIV interventions including 
prevention, social care, assistance with treatment and dosing and ART adherence. 
Social inquiry about HIV must therefore address how the different aspects of its 
constitutive technologies coexist and articulate. Such inquiry allows us to question 
assumptions regarding the boundaries between technologies and permits an 
interrogation of HIV technologies themselves across the diversity, contradictions and 
fractures of their field. Many of the chapters in this volume draw on this expanded 
notion of HIV technologies as the basis for their arguments in relation to different 
aspects of HIV such as prevention, treatment and their intersection; or discourses of 
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‘communication’ and ‘participation’ that operate in both prevention and treatment 
programmes.  
 
A concept that usefully illustrates the importance for HIV social research of 
constructing technologies in newly expanded ways is Rabinow’s formulation of 
biosociality. This concept draws attention to the social relations that give rise to 
contemporary health technologies, but it is also able to describe the desired and 
sometimes unexpected or even counterproductive social effects of technologies. The 
concept emerged first in Rabinow’s ethnography of a French genetics research 
company undergoing rapid transformation in the 1990s (1999). Rabinow pointed out 
that health technologies such as genetic tests and therapies reveal surprising dynamics 
of alliance and conflict between interested parties, including those affected by genetic 
illness and their families, clinicians, researchers, venture capitalists, the popular media 
and government at local, national and, in his particular case, international levels. 
Rabinow also noted that as biomedical technologies are brought into being, their 
social ramifications are not all immediately intelligible. This perspective parallels one 
of the arguments of this volume pertaining to HIV technologies. As we will see, 
several chapters imply the changing nature of HIV technologies and the sometimes 
hidden effects of such changes.  
 
One important insight derived from Rabinow’s work is that the interrogation of health 
technologies necessarily extends to the assumptions that influence how they are used. 
For example, intersecting with the interests of this volume, Rabinow examined French 
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responses to the threat of HIV in the blood transfusion economy as part of his 
ethnography of the genetics research company. He showed how in the French 
situation, abstract principles of the governance of the nation state made it hard to act 
to protect the blood supply from HIV. In particular, the French system relied on 
universalist notions of the inviolable rights of the blood donor to anonymity and the 
related valorisation of the gift and the gift-giver over and above the recipient and their 
rights. This ‘sacralisation’ of a particular social form immobilised attempts to prevent 
HIV coming into and circulating within blood transfusion products. Government 
officials were reluctant to act lest they be accused of transgressing what were seen as 
fundamental human rights to privacy and liberty, axiomatic to French nationhood and 
citizenship. According to Rabinow, such sacralisation is an example of how the 
(sometimes hidden) tensions that reside in forms of citizenship can feature in health 
technologies. As he noted in relation to the example of blood donation: 
The spiritual technology becomes its own worst enemy, activating a dangerous 
machinery that forestalls or inhibits the flourishing of things, practices, and 
assemblages that could well enhance and abet our search for a better form of 
life before they are either understood or communally evaluated through 
experience. (1999: 79)  
 
Rabinow’s comments with regard to HIV and blood donation suggest the salience of 
notions of biosociality for HIV technologies. This approach affords a way of 
investigating how HIV technologies are heavily inflected with questions of 
citizenship, understood in terms of the negative effects of outmoded social forms, the 
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clashing of the multiple understandings of, and interests and investments in, good 
government, the crisis for universalisms in situations of rapid socio-technical change 
and the pursuant ethical challenges for individual and collective practices.  
 
This notion of the biosocial has wide implications and can also be usefully extended 
and differentiated to draw attention to its ramifications for social inquiry. Rose has 
argued that through the science of new genetics and related technical and conceptual 
developments, we have entered the age of “vital politics” and “biological ethics” 
where increased capacity to exact biological control of human life brings with it 
intense political, social and ethical questions  (Rose, 2001: 22). This biopolitics can be 
seen in gene selection technologies that promise the control of disease among future 
populations or notions of permanent ‘cognitive and affective enhancement’ of the 
human species, as it is sometimes called (Savulescu, 2009). Biosociality is therefore 
not only a way of framing health technologies, but due to the far reaching implications 
of socio-technological change, can be used to provide a conceptual framing of 
contemporary society in general. In a recent paper, Rabinow and Rose suggest that 
this biological politics (2006) is at least fourfold. It involves ‘truth discourses,’ most 
obviously but certainly not exclusively in the biological sciences, and particularly, 
today, those which address humans’ ‘vital’ characteristics as living organisms, and try 
to understand, predict, control and change them. Second, biological politics involves 
experts, who claim and are given legitimacy in investigating and proclaiming truth 
discourses, and the relations such experts have with the rest of us, who rely on their 
systems of knowledge. Third, biopolitics focuses on trying to improve people’s health 
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and by implication their whole lives, individually and within groups. The fourth 
aspect of biological politics concerns the means by which people try to make such 
improvements for themselves, by their own self-constitution as health-pursuing 
‘biosocial’ or ‘somatically individualist’ subjects.  
 
Contemporary health technologies in the broad sense in which we have defined them, 
are the technologies of this biological politics. They are a specific subset of 
technologies in general: “hybrid assemblages” (Rose, 2007: 17) of knowledges, 
practices, habits and material resources that have particular effects - in this case, in the 
field of health. Such health technologies are political: they are tied to collective and 
effective decision-making.  They are ethical, that is, they pursue ideals of good 
conduct, though these ideals are often conflicting (MacIntyre, 1984; Rabinow, 2007) .  
And they are importantly implicated with scientific knowledge, not simply suspended 
relativistically in a net of interconnected discourses and practices, but positioned in a 
close relationship to knowledges and strategies that improve and prolong lives 
(Hacking, 2006). HIV technologies of treatment and prevention demonstrate these 
complex relations clearly. They operate at different levels, from the international 
down to the local; they have different interests at each level, varying across fields of 
operation which range from medical research and practice through tactics of self-care 
to artistic production. They often contradict each other and they are nevertheless 
directed at having positive effects on people's lives as 'vital' subjects. Such 
complexities are reflected in the chapters in this volume.  
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Another aspect of biological politics that plays a significant role in this book, is its 
transnationally differentiated character, something that can usefully be understood 
through Chantal Mouffe's (2006) formulation of contemporary politics's multipolar 
and contested nature.  The divergent status of low, middle and high-income countries 
in relation to health technologies is clear, particularly in the HIV treatment case. 
However, such differences do not constitute the entirety of political engagement 
around HIV technologies. As Rabinow and Rose point out (2006), ‘biopower’ cannot 
be equated with politics without becoming an overextended, empty and purely 
descriptive concept. Moreover, transnational differences in HIV technologies cannot 
be reduced to a simple opposition between 'global south' and 'global north' without 
neglecting the complexities of HIV technologies in these locations. People infected or 
affected by HIV are a transnational, sometimes globalised, but also highly 
differentiated group. Their differences appear on many intersecting axes - of for 
instance class, gender, sexuality, ethnicity, ‘race’, religion, and nation-state history 
and politics, as well as the histories and politics of each national epidemic, and 
individuals' own varying health statuses. It is not helpful to reduce such axes to the 
coordinates of imperialist postcolonialism. 
 
Mouffe’s understanding of multiple polarities and ongoing contest as constitutive of 
contemporary political formations allows us to understand HIV technologies in an 
appropriately complex transnational frame. From this perspective, such technologies 
cannot be associated with a single social group, a particular social level, or a specific 
ethical orientation. They are, rather, heterogeneous, multilevelled, and deployed in the 
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service of many different moral discourses.  Such a perspective allows us to analyse 
the contingency and particularity of HIV technologies. The chapters in this book 
assume, for example, that variations between HIV policies within the developing and 
developed worlds are significant elements of biopolitical technologies, rather than 
trivial variations between the ‘have-nots’ and the ‘haves’ of biocapital.  And they 
acknowledge that low-resourced people living with HIV in high-income countries, 
while they are disadvantaged within those countries’ HIV ‘treatment-era’ contexts, 
have importantly different relations to HIV technologies from HIV positive people in 
low-income countries. They are not ‘nested’ postcolonial subjects not ‘really’ living in 
the developed world at all.   
 
We also assert that analyses of HIV technologies need to extend to their psychosocial 
ramifications. Biopolitical inquiry does not often address the psychic interiority of 
citizens, or the memories, thoughts and emotions implicated in socio-technical 
transformations. When it is considered, subjectivity is commonly rendered as one 
reflection of biopower, or self-subjection to forms of pastoral power. In a much-
quoted formulation, Rose (1996) describes subjectivities as Deleuzian 'infoldings' of 
technologies into interiority, a formulation that gives the psychosocial little 
particularity. In contrast, Mouffe's account (2006) provides for a psychosocial space 
constituted by symbolic and subjective disjunctions that are partially bridged by social 
and psychic efforts towards citizenship. Mouffe’s analysis pays attention to 
psychosocial aspects of political processes: to the  imaginings, metaphoric 
articulations and fantasies that support hegemonisation and democratization alike. 
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Butler (2005) similarly captures the subjectifying social and ethical interpellation of 
the self, alongside the powerful inextricability of lives from subjecthoods, while also 
suggesting that sociopolitical differences affect the subject’s structuration at the most 
fundamental, symbolic levels. 
 
Such insistence on the place of the psychosocial within political analysis is important 
for addressing HIV technologies. HIV research, especially research on medical 
technologies’ significance for people affected by the epidemic, is overwhelmingly 
preoccupied with the knowledge, thoughts, beliefs, behaviours and emotions of HIV 
citizens. Such research thus perpetually tries to identify, describe and modify unruly 
‘psychosocial’ factors that disrupt or evade conventional HIV prevention and 
treatment technologies. Reflexivity about this ‘psychosocial’ field appears, in different 
guises, in all the chapters in this volume. The chapters’ varying formulations work to 
map out the complexities and contradictions of HIV's 'psychosocial' technologies.  
 
Overview of chapters 
The chapters in this volume follow a sequence loosely arranged as so: case studies 
that address the governance of HIV prevention and treatment and the intersections of 
these;  reflections on the subjective aspects of HIV technologies derived from close-
focus qualitative research; and investigations of HIV technologies that trouble 
scientific and ontological assumptions about HIV and how the epidemic should be 
governed.  
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Governing HIV treatment and prevention  
In Chapter 2, Catherine Campbell examines four international aid organisation 
interventions in South Africa and Zimbabwe predicated on the concept of community 
participation. Drawing on social psychology and Foucauldian notions of networks of 
power and resistance, Campbell summarises what is known about how to conduct 
interventions effectively, delineating the approaches and methods that underpin what 
she refers to as ‘AIDS competent communities’.  Campbell shows that despite such 
knowledge, international aid agencies often sponsor disappointing interventions. 
Campbell shows that interventions designed to facilitate community participation, can 
actually exert their own power over communities, raising deep questions over the 
participatory aspects of these interventions.  Programme failure is often rationalised in 
terms of external factors and rarely in terms of the conduct of the intervention itself. 
Ironically then, such programmes, ostensibly predicated on community participation 
and empowerment, find ways of explaining why they have not done what they set out 
to do in terms of the failings of communities themselves. Campbell argues that this 
paradox of development governance stymies effective HIV education and support 
interventions.  
 
In Chapter 3, Fareed Abdullah and Corinne Squire present a case study of the rollout 
of ART in the Western Cape of South Africa. The rollout is regarded as an exemplary 
programme for HIV care in transitional country contexts. Abdullah and Squire 
identify and examine what conditions of the rollout made it successful. Drawing on 
Rose’s notions of biopolitics, they show that effectiveness can be attributed to the 
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community-wide dissemination of ART provision to primary care providers and 
engagement with community activists and lay counsellors. This chapter develops the 
concept of HIV citizenship as a way of addressing HIV technologies in the ART 
possibility era.  
 
In the fourth chapter Eric Mykhalovskiy examines the history of a Canadian 
community-based organisation over the course of the HIV epidemic and particularly 
in relation to the advent of ART availability in the mid to late 1990s. Mykhalovskiy 
uses this case to question the integration discourse used by government and other 
agencies to address the relationship between treatment and prevention in the ART era. 
The advent of ART has sponsored much controversy and debate concerning the 
impact it will have on HIV prevention. For some, ART is seen to displace prevention 
and therefore increases HIV transmission. Mykhalovskiy reverses this standard 
critique to examine how HIV prevention imperatives have impacted on, and in some 
cases arguably distorted, the purposes of HIV treatment. Mykhalovskiy shows how 
integration discourse is necessary given the effects of ART for the health of people 
with HIV. However, integration discourse can also be counterproductive for people 
with HIV because of the way it works to strengthen responsibility for HIV prevention, 
among other effects. HIV prevention imperatives rob HIV treatment of its original 
justification as a way of restoring the health of people with HIV and replace it with a 
notion that ART is the means by which people with HIV can be governed to prevent 
transmission of HIV to others. Like Campbell, Abdullah and Squire, Mykhalovskiy 
creates an argument that, to moderate such effects, the practical experience and skills 
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of community agencies need to be incorporated into this new HIV technology of 
integration.  
 
HIV subjectitivies 
In Chapter 5, Lindy Wilbrahim writes about her work in South Africa exploring the 
discursive production of good parenting in relation to the HIV epidemic. Wilbrahim 
formed groups with parents to discuss a text extract from Lovelines, a regular 
magazine column in popular magazines in circulation in South Africa. Lovelines 
addresses parents, encouraging them to reflect on their practices in an effort to 
encourage the prevention of HIV transmission in young people in South Africa. Using 
Foucauldian notions of discourse analysis, Wilbrahim discusses the classing and 
racing of parenting expertise, elaborating an account of good parenting as an HIV 
technology and reflecting on its benefits and drawbacks.  
 
In Chapter 6, Paul Flowers draws on qualitative interviews with men and women with 
HIV residing in Scotland and England to address the psychosocial dimensions of 
living with HIV in the ART possibility era. Flowers provides a detailed picture of the 
physical, mental and relational challenges of HIV diagnosis and health maintenance. 
A key theme in his analysis is to question the discourse of normalisation emanating 
from epidemiological accounts of the ART era and how these marginalise the 
psychosocial experiences of people with HIV. This chapter therefore reflects the 
argument made by Mykhalovskiy in relation to the undesirable aspects of the mixing 
of public health imperatives with the effects of ART for people with HIV.  
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Also drawing on interviews, in Chapter 7 Mark Davis examines personal responses to 
the impact of ART on the risk of transmission in sexual practice. This chapter 
underlines the arguments of Mykhalovskiy and Flowers that epidemiological 
rationalisation of ART positions people with HIV uneasily at the intersection of 
treatment and prevention. Drawing on Rose’s notion of ‘informational biocitizenship’, 
Davis explores the extra-technical aspects of ART-related knowledge and the 
implications for the ethics of sexual relating. This chapter shows how people with 
HIV address these challenges by drawing on their experiences of HIV-related self-
care. Like Campbell and Wilbrahim, Davis argues for increased dialogue with regard 
to the uncertainties, confusions and challenges for sexual ethics that arise in and 
around the use of ART.  
 
New epistemologies and ontologies 
In Chapter 8, Race examines the controversy surrounding so-called barebacking 
among gay men and the related concept of serosorting. Barebacking coincides with the 
ART possibility era and has connections with the use of HIV antibody serostatus to 
determine ‘like with like’ sexual connections where condoms are not used for sexual 
intercourse because HIV transmission is not thought possible. It also resonates with 
the general impact of ART on the status of HIV infection as a serious health concern, 
presumably making sexual intercourse without condoms seem less dangerous than it 
was and therefore enabling cultures of barebacking. Using a Foucauldian framing, 
Race reverses the typical discourse regarding barebacking to reveal how the striving 
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for ethical, sexual relationality underpins the practice. Race therefore addresses 
barebacking as a HIV technology in its own right. He explores its dual status as both a 
form of autonomy on the part of some gay men with HIV and as transgressive of what 
is taken to be good HIV citizenship under the imperatives of HIV prevention. Race 
shows that this duality underpins behavioural research seeking to explain barebacking 
behaviour. He argues that useful research needs to be reflexive with this duality.  
 
In the last substantive chapter in this volume, Marsha Rosengarten and Mike Michael 
examine the ethical controversies surrounding the clinical trials for pre-exposure 
prophylaxis (PrEP) in countries in Africa and Asia. PrEP is an experimental form of 
biomedical HIV prevention where those at risk of HIV transmission take ART on a 
regular basis to reduce the likelihood of HIV infection. PrEP is therefore emblematic 
of the overlapping of treatment and prevention technologies. Rosengarten and Michael 
examine clinical trials for PrEP as sites of enormous complexity for HIV governance 
with controversial and potentially unknowable effects combined with opportunities 
for using biomedical technologies in innovative and productive ways. Because PrEP is 
squarely a biomedical form of HIV prevention it is both harbinger of the new 
formulations of HIV technology and crystallises many of the themes raised in previous 
chapters. Rosengarten and Michael show how clinical trials of PrEP raise questions of 
citizenship, controversial engagements with local trial communities and the impact of 
ART on HIV prevention and vice versa. This chapter addresses the extra-material in 
HIV technologies and extends to a discussion of ethics and science and the ontological 
status of the HIV virus itself. 
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In the final chapter, Davis and Squire reflect on the arguments developed in each of 
the chapters and return to some of the key points raised in this introduction. We will 
focus on some crosscutting dimensions that will appear in the chapters, in particular 
the clashing and synergies apparent in the articulations of HIV treatment and 
prevention technologies and struggles over truth claims that have significance in the 
governance of a treatment possibility epidemic. We will also reflect on the forms of 
HIV citizenship implied in transnational and local diversity and draw attention to the 
underlying ‘pragmatics’ that inform the chapters in this volume and that have 
relevance for future inquiry and intervention.  
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